EDIT

Editas MedicineC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$4.50

+51.0% vs current

Most likely

Base case

40%

Probability

Target price

$2.80

-6.0% vs current

B-

Bear case

30%

Probability

Target price

$1.40

-53.0% vs current

AI sentiment snapshot

Latest data as of 2026-06-12

AI commentary

Sentiment remains cautious and monitoring-oriented. Primary-source evidence is better than the stock action implies: management reiterated the 2026 EDIT-401 clinical path and the company added meaningful capital in late May, but the market still has to see execution beyond preclinical data and absorb the financing overhang [#SEC-8K-2026-05-05] [#8-K-2026-05-26]. Third-party post-earnings commentary noted shares were down 12.4% since the Q1 report, and broad analyst-revision evidence is still thin, which argues for a low-conviction stance rather than a bullish re-rate call [#PR-EARNINGS-2026-06-04].

RankAlpha Sentiment Codex - 2026-06-12

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-30eventEDIT-401 IND/CTA timing is the clearest mid-2026 proof pointHigh impact

Management said EDIT-401 remains on track for a first-in-human study later in 2026, with GLP toxicology work ongoing and IND/CTA submission targeted by mid-2026, making regulatory readiness the most important near-term operating checkpoint for the in vivo strategy [#SEC-8K-2026-05-05].

2026-06-30catalystMay financing resets cash but leaves dilution and warrant overhangHigh impact

Editas disclosed an underwritten public offering of 55.6 million shares with accompanying warrants at a combined public offering price of $2.25 and estimated about $117.0 million of net proceeds, which helps runway but likely keeps near-term trading sensitive to dilution digestion and future warrant-related supply [#8-K-2026-05-26].

2026-12-31catalystFirst-in-human EDIT-401 execution drives any durable re-ratingHigh impact

Editas expects to initiate a first-in-human HeFH study later in 2026, report early human proof-of-concept by the end of 2026, and deliver topline dose-finding data in 2027; with the story now centered on one lead in vivo program, successful early human translation is the main path to a sustained re-rating [#SEC-8K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-12 • Updated nightlySource: Internal modelMethodology